Cargando…

Why and how does light therapy offer neuroprotection in Parkinson's disease?

Detalles Bibliográficos
Autor principal:	Mitrofanis, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436350/ https://www.ncbi.nlm.nih.gov/pubmed/28553332 http://dx.doi.org/10.4103/1673-5374.205092

Ejemplares similares

How and why does photobiomodulation change brain activity?
por: Mitrofanis, John, et al.
Publicado: (2020)

Lights for epilepsy: can photobiomodulation reduce seizures and offer neuroprotection?
por: Torres-Martinez, Napoleon, et al.
Publicado: (2022)

Targeting the body to protect the brain: inducing neuroprotection with remotely-applied near infrared light
por: Johnstone, Daniel M., et al.
Publicado: (2015)

Exploring the use of transcranial photobiomodulation in Parkinson's disease patients
por: Hamilton, Catherine, et al.
Publicado: (2018)

How does zebrafish support new strategies for neuroprotection and neuroregeneration in hypoxia-related diseases?
por: Silva, Emerson S., et al.
Publicado: (2016)

The code of light: do neurons generate light to communicate and repair?
por: Moro, Cecile, et al.
Publicado: (2021)

Neuroprotective Surgical Strategies in Parkinson’s Disease: Role of Preclinical Data
por: Torres, Napoleon, et al.
Publicado: (2017)

Pretreatment of caffeine leads to partial neuroprotection in MPTP model of Parkinson's disease
por: Bagga, Puneet, et al.
Publicado: (2016)

Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease
por: Johnstone, Daniel M., et al.
Publicado: (2016)

Bacterial melanin in rat models of Parkinson's disease: a potential neuroprotective strategy
por: Petrosyan, Tigran
Publicado: (2015)

Evaluating rehabilitation interventions in Parkinson's disease with functional MRI: a promising neuroprotective strategy
por: Mallio, Carlo Augusto, et al.
Publicado: (2015)

The Wnt/β-catenin signaling: a multifunctional target for neuroprotective and regenerative strategies in Parkinson’s disease
por: Serafino, Annalucia, et al.
Publicado: (2022)

Why is there motor deterioration in Parkinson’s disease during systemic infections-a hypothetical view
por: Brugger, Florian, et al.
Publicado: (2015)

Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease
por: Thornton, Emma, et al.
Publicado: (2015)

Newfound physiological function of FAIM protein offers hope of novel disease-modifying therapy for Alzheimer’s disease
por: Balaj, Allison R., et al.
Publicado: (2023)

Mitotic Recombination: Why? When? How? Where?
por: LaFave, Matthew C., et al.
Publicado: (2009)

Why and How to Globalize Traditional Chinese Medicine
por: Cheng, Yung-Chi
Publicado: (2011)

Neuroprotective therapy for retinal neurodegenerative diseases by stem cell secretome
por: Usategui-Martín, Ricardo, et al.
Publicado: (2020)

Diabetic retinopathy: neurovascular disease requiring neuroprotective and regenerative therapies
por: Oshitari, Toshiyuki
Publicado: (2021)

Why does caloric restriction increase life and healthspan? The ‘clean cupboards’ hypothesis
por: Speakman, John R
Publicado: (2020)

Interleukin 4-induced neuroprotection and regulation of microglia activation as a therapeutic approach in the MPTP model of Parkinson's disease
por: Spittau, Björn
Publicado: (2017)

Why Temperature Screening for Coronavirus Disease 2019 With Noncontact Infrared Thermometers Does Not Work
por: Wright, William F, et al.
Publicado: (2020)

Cell Therapies for Parkinson's Disease
por: Irion, Stefan
Publicado: (2019)

Why a Right to Health Makes No Sense, and What Does
por: Hahn, Robert A., et al.
Publicado: (2020)

Identifying specific RGC types may shed light on their idiosyncratic responses to neuroprotection
por: Vidal-Sanz, Manuel, et al.
Publicado: (2015)

Sulindac for stroke treatment: neuroprotective mechanism and therapy
por: Modi, Jigar Pravinchandra, et al.
Publicado: (2014)

Why 90% of clinical drug development fails and how to improve it?
por: Sun, Duxin, et al.
Publicado: (2022)

Adapting improvements to context: when, why and how?
por: Ovretveit, John, et al.
Publicado: (2018)

Does Black vs. White race affect practitioners’ appraisal of Parkinson’s disease?
por: Harris, Shana, et al.
Publicado: (2023)

Walking and talking the tree of life: Why and how to teach about biodiversity
por: Ballen, Cissy J., et al.
Publicado: (2017)

How does resveratrol influence the genesis of some neurodegenerative diseases?
por: Tellone, Ester, et al.
Publicado: (2016)

Potential role of biofeedback therapy for Parkinson’s disease
por: Kotani, Naoya, et al.
Publicado: (2021)

Why Does the Omicron Variant Largely Spare Olfactory Function? Implications for the Pathogenesis of Anosmia in Coronavirus Disease 2019( )
por: Butowt, Rafal, et al.
Publicado: (2022)

Lights at night: does photobiomodulation improve sleep?
por: Valverde, Audrey, et al.
Publicado: (2022)

Why does the Aβ peptide of Alzheimer share structural similarity with antimicrobial peptides?
por: Pastore, Annalisa, et al.
Publicado: (2020)

Targeting chaperone-mediated autophagy for Parkinson’s disease therapy
por: Wang, Yi-Ting, et al.
Publicado: (2023)

Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson’s disease: implication of acrolein and TRPA1
por: Shi, Liangqin, et al.
Publicado: (2021)

Preemptive kidney transplantation: why, when, and how?
por: Moura, Ana Flávia, et al.
Publicado: (2022)

What Can Systems Theory of Networks Offer to Biology?
por: Rajapakse, Indika, et al.
Publicado: (2012)

Drugging SUMOylation for neuroprotection and oncotherapy
por: Bernstock, Joshua D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a87l9r9nl7sg03i46jkapomq7p